Since the emergence of the novel coronavirus (SARS-CoV-2) and the start of the ongoing covid-19 pandemic, scientific laboratories have found themselves confronted with two difficult and seemingly unreconcilable challenges.
On the one hand, the efforts to find a treatment for Covid-19 has increased the pressure on the biopharmaceutical industry to develop new therapeutics faster. At the same time, biopharmaceutical companies and CDMOs are required to work differently – at a social distance. Something that can severly influence laboratory effectiveness and the dynamics of discovery.
As an example, 48% of scientific research labs across the globe stated that they had been forced to close temporarily, according to a survey in April 2020. In fact, many biopharmaceutical developers are still searching for ways to work more effectively at a distance, in a new world.
IDBS Bioprocess Solution can provide the basis for effective biopharmaceutical development of vaccines and anti-viral therapeutics by simplifying and improving the handling of data.
Our cloud-based platform allows for convenient capture, storage and access to contextualized, high-quality data – and the sharing of that data within your whole organization. Together with our customers, we design simpler and more effective processes for greater discoveries in a new world. We call it distant socializing.
Right now, we offer free use of our software and fast deployment – and our full support – to anyone working toward COVID-19 therapeutics.
An informative look at what the cloud actually is and why your business should take advantage of it to transform your R&D process at an affordable cost
Research collaborations allow researchers to ask questions they wouldn’t be able to ask if they worked alone
How to reduce R&D costs in a global marketplace while continuing to deliver competitive product